Efficient transient transfection of human multiple myeloma cells by electroporation - An appraisal

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Steinbrunn, Torsten ^a   Chatterjee, Manik ^a   Bargou, Ralf C ^a   Stühmer, Thorsten ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; OLIGONUCLEOTIDE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ARTICLE; CELL MEMBRANE POTENTIAL; CELL POPULATION; CELL SEPARATION; CELL VIABILITY; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ELECTRIC POTENTIAL; ELECTROPORATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA CELL LINE; MYELOMA CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTOCOL COMPLIANCE; TRANSIENT TRANSFECTION; CELL SURVIVAL; FLOW CYTOMETRY; GENE SILENCING; GENE TRANSFER; GENETIC TRANSFECTION; GENETICS; METABOLISM; MULTIPLE MYELOMA; PROCEDURES; REPORTER GENE; RNA INTERFERENCE; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; ELECTROPORATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE TRANSFER TECHNIQUES; GENES, REPORTER; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MULTIPLE MYELOMA; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84902477582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097443     Document Type: Article

References (32)

1. Kuehl WM, Bergsagel PL (2012) Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 122: 3456-3463.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, et al. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403.
3. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
4. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, et al. (2013) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia.
5. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, et al. (2012) Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 9: 135-143.
6. Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, et al. (2013) Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia 27: 226-232.
7. Chesi M, Bergsagel PL (2013) Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol 97: 313-323.
8. Fonseca R, Monge J (2013) Myeloma: classification and risk assessment. Semin Oncol 40: 554-566.
9. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, et al. (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120: 1067-1076.
10. Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Nat Rev Cancer 12: 335-348.
11. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, et al. (2014) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25: 91-101.
12. Brito JL, Davies FE, Gonzalez D, Morgan GJ (2008) Streptolysin-O reversible permeabilisation is an effective method to transfect siRNAs into myeloma cells. J Immunol Methods 333: 147-155.
13. Brito JL, Brown N, Morgan GJ (2010) Transfection of siRNAs in multiple myeloma cell lines. Methods Mol Biol 623: 299-309.
14. Gómez-Benito M, Balsas P, Carvajal-Vergara X, Pandiella A, Anel A, et al. (2007) Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. Cell Signal 19: 844-854. (Pubitemid 46275374)
15. Muto A, Hori M, Sasaki Y, Saitoh A, Yasuda I, et al. (2007) Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 6: 987-994. (Pubitemid 46554568)
16. Walters DK, Jelinek DF (2002) The effectiveness of double-stranded short inhibitory RNAs (siRNAs) may depend on the method of transfection. Antisense Nucleic Acid Drug Dev 12: 411-418.
17. Zhang HR, Chen JM, Zeng ZY, Que WZ (2013) Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. J Int Med Res 41: 584-595.
18. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, et al. (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65: 5399-5407. (Pubitemid 40827353)
19. Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, et al. (2012) Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res 72: 757-768.
20. Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, et al. (2009) Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res 69: 5082-5090.
21. Chatterjee M, Stühmer T, Herrmann P, Bommert K, Dörken B, et al. (2004) Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 104: 3712-3721. (Pubitemid 39564449)
22. Steinbrunn T, Siegmund D, Andrulis M, Grella E, Kortüm M, et al. (2012) Integrin-linked kinase is dispensable for multiple myeloma cell survival. Leuk Res 36: 1165-1171.
23. Steinbrunn T, Stühmer T, Gattenlöhner S, Rosenwald A, Mottok A, et al. (2011) Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood 117: 1998-2004.
24. Stühmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, et al. (2005) Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 106: 3609-3617. (Pubitemid 41609200)
25. Zöllinger A, Stühmer T, Chatterjee M, Gattenlöhner S, Haralambieva E, et al. (2008) Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 112: 3403-3411.
26. Burger R, Guenther A, Bakker F, Schmalzing M, Bernand S, et al. (2001) Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokineregulated tumor model for plasmacytoma. Hematol J 2: 42-53. (Pubitemid 32266385)
27. Uphoff CC, Drexler HG (2004) Detecting Mycoplasma contamination in cell cultures by polymerase chain reaction. Methods Mol Med 88: 319-326.
28. Logue SE, Elgendy M, Martin SJ (2009) Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. Nat Protoc 4: 1383- 1395.
29. Haan C, Behrmann I (2007) A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. J Immunol Methods 318: 11-19. (Pubitemid 46026809)
30. Stroh T, Erben U, Kühl AA, Zeitz M, Siegmund B (2010) Combined pulse electroporation-a novel strategy for highly efficient transfection of human and mouse cells. PLoS One 5: e9488.
31. Mello de Queiroz F, Sánchez A, Agarwal JR, Stühmer W, Pardo LA (2012) Nucleofection induces non-specific changes in the metabolic activity of transfected cells. Mol Biol Rep 39: 2187-2194.
32. Kandušer M, Miklavčič D, Pavlin M (2009) Mechanisms involved in gene electrotransfer using high- and low-voltage pulses-an in vitro study. Bioelectrochemistry 74: 265-271.